Other events

IRB Barcelona PhD Retreat 2014

14 Nov 2014 - 15 Nov 2014

Open registration for the first IRB Barcelona PhD student retreat

The deadline for registration is 10th October, after this date PhD students interested in participating should contact irb.phdretreat@irbbarcelona.org



The IRB Barcelona PhD Retreat aims to bring its PhD student community together to exchange experiences and knowledge. This event will include talks and poster sessions presented by and for students. Furthermore, former IRB Barcelona PhD students will be invited to give presentations on their current research, thus providing participants an insightful view into career options after IRB Barcelona. Science apart, this retreat will also serve to promote inter-programme relations through a range of fun social activities.



  • To present scientific data (oral presentation or poster)
  • To discuss data presented by others students
  • To enhance interaction between students



We thank the generous contribution of our main sponsors:


Registration deadline 10th October, 2014:

  • IRB PhD students: To complete your inscription, the registration fee should be paid before 17th October 2014. The total amount is 40 euros per student (Including overnight stay at the Hotel Campus): 20 euros are covered by the student and 20 euros by his/her Group Leader (GL).



Abstract submission:

Each IRB Barcelona PhD student is requested to submit a short abstract in English (max. 400 words). Abstracts have to be uploaded online before 10th October 2014. Students who are selected to give a talk or to present a poster will receive confirmation before 15th October, 2014. Download format for abstract (Click here)

The PhD Retreat will last two days. We will begin on Friday morning while finishing on Saturday afternoon. All the events will take place at the same venue, including the sleep in the hotel.


Preliminary schedule


More information and details:

PhD students in the final year of their PhD project:

  • Abstracts from PhD students in the final year of their PhD project will be selected for an oral presentation.
  • Oral Presentation: 10-min presentation + 5-min discussion.


All other PhD students:

  • Poster presentation. Abstracts from PhD students in the 2nd and 3rd year of their PhD project will be selected for poster presentation. This is not obligatory for those who started their PhD project in September 2014 or for students selected for an oral presentation.
  • Poster Walks. Students will be divided into small groups from various disciplines. In each group there will be a chair, one of the last year students giving oral presentations. Each author will present his/her poster to the rest of their group during the poster walk. Each poster presentation will include a 5-min talk + 5-min discussion. You are requested to keep to the times limits, otherwise the session chair may intervene.


Invited Speakers: former IRB Barcelona PhD Students

  • Oral presentation: 40-min presentation + 10-min discussion.




Social programme:

  • Pub quiz
  • Sports activity


Prizes will be awarded for: the best talk and best poster presentation.

Tel. +34 93 580 83 53
Fax +34 93 580 89 78


By car
The Hotel Campus is situated 19 km from Barcelona.
Motorway AP-7, direction Girona-France, exit "Universitat Autònoma".
Motorway C-58, direction Sabadell-Terrassa, exit number 8, connecting with AP-7 direction to Tarragona. On the AP-7 take the side lane and after 1000 m leave at the exit "Universitat Autònoma".

Introduce the following addresses: Carrer de Joan Villa Puig Cerdanyola del Vallès.
Coordinates: 41.499999, 2.095827

By train
Ferrocarrils de la Generalitat de Catalunya (FGC):
Lines Barcelona/Sabadell (S2) and Barcelona/UAB (S55), Bellaterra station. The journey from Barcelona takes 40 minutes. Trains run approximately every 10 minutes. You can consult the timetable on the website of FGC: http://www.fgc.net.
From Bellaterra station you need to walk 10 minutes to reach the Hotel.

By bus
From Barcelona: the company SARBUS runs a service from Barcelona (Fabra i Puig) to the Universitat Autònoma (UAB) every 30 minutes. For more information, see: www.sarbus.com.

By plane
From El Prat Airport, Barcelona:
Cercanías RENFE or Aerobús to Plaça Catalunya; from there take Ferrocarrils de la Generalitat de Catalunya, lines S2 or S55 to Bellaterra.

Dr. David Vilchez, Principal Investigator at CECAD

David Vilchez obtained his PhD from IRB in 2008. Working at Joan Guinovart´s lab he studied Lafora Disease and brain glycogen. After he worked at the Salk Institute in California and at the University of California Berkeley, where his studies focused on aging in C. elegans. From his work at Dillin´s lab he successfully publishes two Nature papers. Actually David talented career continues as a Principal Investigator at the Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD). Where he is interested in studying how human embryonic stem cells maintain the integrity of their proteome.

Selected Publications:

  • Vilchez D, Boyer L, Lutz M, Merkwirth C, Morantte I, Tse C, Spencer B, Page L, Masliah E, Berggren WT, Gage FH and Dillin A (2013) FOXO4 is necessary for neural differentiation of human embryonic stem cell. Aging Cell 12 (3): 518-522.
  • Vilchez D, Simic M, Dillin A (2013) Proteostasis and aging of stem cells. Trends in Cell Biology
  • Vilchez D, Boyer L, Morantte I, Lutz M, Merkwirth C, Joyce D, Spencer B, Page L, Maslias E, Berggren WT, Gage FH and Dillin A (2012). Increased proteasome activity in human embryonic stem cells is regulated by PSMD11. Nature 489 (7415): 304-308.
  • Vilchez D, Morantte I, Liu Z, Douglas PM, Merkwirth C, Rodrigues AP, Manning G and Dillin A (2012). RPN-6 determines C. elegans longevity under proteotoxic stress conditions. Nature 489 (7415): 263-268.


Dr. Georgina Sorrosal de Luna, Innovation Developer at VHIR

Georgina Sorrosal de Luna obtained her PhD from IRB in 2010, where she studied the secreted serine protease-like protein Scarface on Drosophila embryo under the direction of Marco Milán. She then decided to focus her career into Science management. From 2010-2012 she worked at Associació de Biotecnòlegs de Catalunya (ABSTEC), a non-profit association, organizing different congresses and activities to link research & business in the biotech and biomedical field. In 2011, she joined Advancell biotech company, focused in drug development, where she worked as a Project Manager leading a clinical trial in multiple sclerosis for 3 years. Currently Georgina has a position as Innovation Developer at Vall d’Hebron Institute of Research (VHIR).

Selected Publications:

  • Sorrosal G, Pérez L, Herranz H, Milán M. (2010) Scarface, a secreted serine protease-like protein, regulates polarized localization of laminin A at the basement membrane of the Drosophila embryo. EMBO Reports 11(5):373-9.
  • Bejarano F, Luque C M, Herranz H, Sorrosal G, Rafel N, Pham T T, Milán M. (2008) A gain-of-function suppressor screen for genes involved in dorsal-ventral boundary formation in the Drosophila wing. Genetics. 178(1):307-23.


Dr. Carlos Garcia-Echeverria, Global Head of Small Molecule Drug Discovery at Sanofi-Aventis

Carlos Garcia-Echeverria, Ph.D., is the current Global Head of Small Molecule Drug Discovery at Sanofi-Aventis. Before, he has served as Global Head of Oncology Medicinal Chemistry & Pharmacology and Deputy Global Head of Oncology Drug Discovery and Preclinical Development at Sanofi-Aventis since April 2010.

From 1993 to 2010, Dr. Garcia-Echeverria held several positions of increasing responsibility at the Novartis Institutes for BioMedical Research. In his last position as Executive Director of Oncology Drug Discovery, he was responsible for managing the late drug discovery programs –lead to first-patient-first-visit- at the Novartis Oncology Research site in Basel, Switzerland. His research activities have been mainly focused on the identification and development of inhibitors of protein and lipid kinases, proteolytic enzymes and antagonists of intracellular protein-protein interactions. Dr Garcia-Echeverria has made significant contributions to the identification and development of targeted cancer therapies and has advanced seven drug candidates to Phase I/II clinical trials.

He is an inventor on 30 patents, and has published more than 150 peer-reviewed articles, book chapters and review papers. Dr Garcia-Echeverria received his Ph.D. in organic chemistry from the University of Barcelona (Spain) in 1993, doing his thesis work in the group of Prof. Ernest Giralt.

He is Senior Editor of “Chemical Biology & Drug Design” and board member of “Drug Design Reviews-Online”, “Expert Opinion on Therapeutic Targets”, “Journal of Peptide Research and Therapeutics”, “Current BioData”, “Recent Patent Reviews on Anti-cancer Drug Discovery”, and “The Open Cancer Journal”. Dr Garcia-Echeverria received the Leonidas Zervas Award from the European Peptide Society in 2006.

We thank the generous contribution of our main sponsors: